Related Experiment Video
Updated: Oct 4, 2025

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
EZH2 Inhibitors: The Unpacking Revolution
1Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
EZH2 inhibitors can reverse gene silencing in acute myeloid leukemia (AML) cells. This pretreatment enhances chemotherapy effectiveness, leading to increased cancer cell death and reduced side effects.
Area of Science:
- Epigenetics and Cancer Biology
- Chromatin Regulation
- Molecular Oncology
Background:
- Histone H3 lysine 27 trimethylation (H3K27me3) is a repressive chromatin mark linked to gene silencing.
- Enhancer of zeste homolog 2 (EZH2) is the enzyme responsible for catalyzing H3K27me3.
- Acute myeloid leukemia (AML) is a hematological malignancy often characterized by aberrant gene expression.
Purpose of the Study:
- To investigate the effect of EZH2 inhibition on H3K27me3-marked chromatin in AML cells.
- To determine if EZH2 inhibition can sensitize AML cells to DNA-damaging chemotherapeutic agents.
- To explore the potential of combining EZH2 inhibitors with chemotherapy for improved AML treatment.
Main Methods:
- Treatment of AML cells with EZH2 inhibitors.
- Assessment of chromatin accessibility and DNA damage.
- Evaluation of apoptosis induction and gene expression changes following combination therapy.
Main Results:
- Pretreatment with EZH2 inhibitors successfully opened H3K27me3-marked chromatin in AML cells.
- This chromatin modulation significantly enhanced DNA damage and apoptosis induced by topoisomerase II inhibitors (doxorubicin, etoposide).
- The combination of EZH2 inhibitor and doxorubicin promoted the expression of proapoptotic genes, contributing to AML cell death.
Conclusions:
- EZH2 inhibition can overcome chromatin-based gene silencing in AML.
- Combining EZH2 inhibitors with DNA-damaging agents represents a promising strategy to improve AML treatment efficacy.
- This approach may allow for lower chemotherapy doses, potentially reducing treatment-related toxicity.
More Related Videos
10:26Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
E2 Reaction: Kinetics and Mechanism
E2 Reaction: Stereochemistry and Regiochemistry
When a substrate with two different β hydrogens undergoes an E2 elimination, the presence of a strong base can yield two regioisomeric alkenes. The more-substituted alkene is the major...
Antihypertensive Drugs: Thiazide-Class Diuretics